secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001193125-25-080277
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront
--------------------------------------------------------------------------------

- Upfront payment of $12M; eligible for up to $345M in success-based research, development, and commercial milestones.
- BI gets exclusive worldwide license to develop and commercialize CUE-501 and other B cell depletion molecules.
- Cue prohibited from developing or commercializing any B cell depletion molecules during the 4-year research term.
- BI will pay research support during research term; royalties on net sales subject to standard reductions.
- Amendment with Einstein College of Medicine allows sublicense to BI and adjusts upstream payment obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525080277/0001193125-25-080277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525080277/d894534d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-080277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer